MORE ON ABOUT ZILXI
Minocycline has been shown to exhibit anti-inflammatory properties*
Minocycline has been proven to be effective in the fight against inflammatory lesions of rosacea for the first time with Zilxi
Oral tetracyclines are a mainstay in rosacea treatment. This is thought to be due to their anti-inflammatory properties.3* However, oral tetracyclines come with challenges
*The mechanism of action of minocycline in treating inflammatory lesions in adults with rosacea is unknown.
†A phase 2 dose-finding study assessed the efficacy of topical minocycline foam 1.5% and topical minocycline foam 3% in comparison with vehicle. While both doses of topical minocycline were superior to vehicle in reduction of inflammatory lesions and in improving subjects’ Investigator’s Global Assessment (IGA) scores, no additional clinical benefit for topical minocycline foam 3% was observed compared to topical minocycline foam 1.5%.2
Zilxi is enabled by a proprietary foam vehicle that leverages Molecule Stabilizing Technology (MST)™
Developed with precision
Enables unstable molecules to be placed into a dermatologically purposeful vehicle for stable topical delivery5,6
Leverages micronized particles to increase coverage and penetration7,8
Formulated for efficiency
Emollient foams like Zilxi have a variety of functional advantages including:
Moisturizing and free of drying agents
The vehicle contains naturally moisturizing ingredients10,11‡:
The foam vehicle is surfactant-free and does NOT contain drying agents, such as ethyl alcohol10
‡Zilxi 1.5% topical foam contains the following inactive ingredients: soybean oil, coconut oil, light mineral oil, cyclomethicone, cetostearyl alcohol, stearic acid, myristyl alcohol, hydrogenated castor oil, white wax (beeswax), stearyl alcohol, docosanol, and propellants (butane + isobutane + propane).10
Contraindications
Persons who have shown hypersensitivity to any of the tetracyclines or any other ingredient in ZILXI.
Warnings and Precautions
Flammability: The propellant in ZILXI is flammable. Instruct the patient to avoid fire, flame, and smoking during and immediately following application.
ZILXI is a topical foam. While systemic absorption of ZILXI is low, and serious adverse reactions were not seen in clinical studies, the following adverse reactions associated with oral minocycline should be considered:
Adverse Reactions
The most common adverse reaction reported during clinical trials of ZILXI was diarrhea.
Indications and Usage
ZILXI (minocycline) topical foam, 1.5% is a tetracycline-class drug indicated for the treatment of inflammatory lesions of rosacea in adults.
Limitations of Use: This formulation of minocycline has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, ZILXI should be used only as indicated.
Please click to access full Prescribing Information.
Contraindications
Persons who have shown hypersensitivity to any of the tetracyclines or any other ingredient in ZILXI.
Warnings and Precautions
Flammability: The propellant in ZILXI is flammable. Instruct the patient to avoid fire, flame, and smoking during and immediately following application.
ZILXI is a topical foam. While systemic absorption of ZILXI is low, and serious adverse reactions were not seen in clinical studies, the following adverse reactions associated with oral minocycline should be considered:
Adverse Reactions
The most common adverse reaction reported during clinical trials of ZILXI was diarrhea.
Indications and Usage
ZILXI (minocycline) topical foam, 1.5% is a tetracycline-class drug indicated for the treatment of inflammatory lesions of rosacea in adults.
Limitations of Use: This formulation of minocycline has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, ZILXI should be used only as indicated.
Please click to access full Prescribing Information.
REFERENCES